Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyretin-Mediated (ATTR) Amyloidosis

October 24, 2025

“Closing gaps in care for people with transthyretin-mediated (ATTR) amyloidosis starts with listening to patients and families about what truly matters in their care journey.”

These words - shared by Christine Chiti, clinical TTR nurse specialist at the Royal Free Hospital, UK, during the International ATTR 2025 Meeting for Patients and Doctors in Baveno, Italy - capture the spirit behind World Amyloidosis Day 2025. The day brings together members of the ATTR community to raise awareness, share experiences and drive action for change.

Enhancing understanding of this life-threatening disease and ensuring that care reflects the realities of those living with it are vital goals shared across the community. In recognition of World Amyloidosis Day, Alnylam is proud to stand alongside patients, clinicians, researchers and advocates working to strengthen awareness, education and support for holistic, person-centered care in ATTR. 

ATTR is a complex, multi-system condition that can affect multiple parts of the body, including the nerves, heart and other organs. Fatigue, pain, mobility limitations and emotional strain all influence how a person experiences their illness. Because the disease impacts multiple systems, diagnosis can take years and often requires input from several specialists before connections are made. Even after diagnosis, care can be fragmented and isolating, with patients navigating between various medical disciplines to manage their condition. 

For people living with ATTR, care must extend beyond symptom management, encompassing physical, mental, and emotional health to ensure a holistic approach to well-being and quality of life.” - Dr. Caroline Morbach, Cardiologist, University Hospital Würzburg, Germany 

L to R: Dr. Caroline Morbach, Sean and Dr. Beata Maj

No one understands these realities better than the people at the center of them. One of those people is Sean, who lives with ATTR with cardiomyopathy (ATTR-CM). After a long journey to diagnosis, Sean began treatment and has since focused on raising awareness, supporting others in the community and finding strength through connection and creativity. 

Living with ATTR has taught me that it’s about more than managing symptoms. It's about care that embraces every aspect of my well-being, recognizing that a full life involves more than just treatment. Staying connected, finding purpose and supporting each other truly make a difference.” - Sean, living with ATTR-CM

Sean’s story is one of many that highlights the need for more holistic, person-centered care both inside and outside the clinical setting. That is why Alnylam is working closely with a multidisciplinary group comprising cardiologists, specialist nurses, patient advocates, patients and primary care specialists to develop a series of recommendations aimed at strengthening coordination, improving understanding of patient needs and supporting a more connected approach to care. 

We often hear from individuals living with ATTR who feel their care is fragmented. Our goal is to help connect the pieces across disciplines and ensure comprehensive care that supports patients' physical, emotional, social, and spiritual needs, both inside and outside the clinical setting. We want patients, caregivers and their families to feel seen and supported. Working hand in hand with the ATTR community is essential to driving meaningful change, and we look forward to continuing this collaboration to advance truly patient-centered care.” - Beata Maj, M.D., VP, Head of Medical Affairs, International TTR, Alnylam

Tags

Patient Focus, Articles, Amyloidosis, hATTR amyloidosis, World Amyloidosis Day

Related Content See All News ›
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
Patient Focus The Importance of Self-Advocacy: Supporting Patients and Caregivers in Their Rare Disea ...

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
Patient Focus The Importance of Self-Advocacy: Supporting Patients and Caregivers in Their Rare Disea ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site